Log in

NASDAQ:OPTN - OptiNose Stock Price, Forecast & News

$7.46
-0.43 (-5.45 %)
(As of 02/21/2020 04:00 PM ET)
Today's Range
$7.31
Now: $7.46
$7.88
50-Day Range
$6.86
MA: $7.99
$9.23
52-Week Range
$4.44
Now: $7.46
$11.66
Volume107,751 shs
Average Volume165,844 shs
Market Capitalization$310.19 million
P/E RatioN/A
Dividend YieldN/A
Beta0.78
OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OPTN
CUSIPN/A
Phone267-364-3500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.07 million
Book Value$2.88 per share

Profitability

Net Income$-106,660,000.00
Net Margins-419.37%

Miscellaneous

Employees102
Market Cap$310.19 million
Next Earnings Date3/4/2020 (Estimated)
OptionableNot Optionable

Receive OPTN News and Ratings via Email

Sign-up to receive the latest news and ratings for OPTN and its competitors with MarketBeat's FREE daily newsletter.


OptiNose (NASDAQ:OPTN) Frequently Asked Questions

What is OptiNose's stock symbol?

OptiNose trades on the NASDAQ under the ticker symbol "OPTN."

How were OptiNose's earnings last quarter?

OptiNose Inc (NASDAQ:OPTN) released its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.69) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.69). The business earned $12.40 million during the quarter, compared to the consensus estimate of $8.56 million. OptiNose had a negative return on equity of 137.60% and a negative net margin of 419.37%. View OptiNose's Earnings History.

When is OptiNose's next earnings date?

OptiNose is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for OptiNose.

What price target have analysts set for OPTN?

6 Wall Street analysts have issued 12-month price objectives for OptiNose's shares. Their forecasts range from $20.00 to $29.00. On average, they expect OptiNose's stock price to reach $24.83 in the next year. This suggests a possible upside of 232.9% from the stock's current price. View Analyst Price Targets for OptiNose.

What is the consensus analysts' recommendation for OptiNose?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OptiNose in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OptiNose.

What are Wall Street analysts saying about OptiNose stock?

Here are some recent quotes from research analysts about OptiNose stock:
  • 1. According to Zacks Investment Research, "OptiNose Inc. is a specialty pharmaceutical company. It focused on the development and commercialization of products for patients treated by ear, nose and throat or ENT and allergy specialists. The company's lead product consists of XHANCE nasal polyps, XHANCE Chronic sinusitis, OPN-300, OPN- 021 and AVP-825 which are in clinical stage. OptiNose Inc. is headquartered in Pennsylvania, USA. " (1/29/2020)
  • 2. Cantor Fitzgerald analysts commented, ". Post 1Q19, we are reiterating our OW rating and $27 12- month PT for OPTN. Despite a lumpy Xhance initial launch, we believe we are beginning to see Xhance gain traction, which supports our confidence in the peak sales potential of the product. In 2019, we believe the increased access, better affordability, the sales force expansion and increased awareness of the good efficacy data should continue to drive script growth throughout the year, and beyond. OPTN has evolved aspects of its launch strategy, which we view as positive and believe are beginning to pay dividends. We continue to take a conservative approach to Xhance revenue in 2019 while the updated launch strategy is fully implemented." (5/9/2019)

Has OptiNose been receiving favorable news coverage?

News headlines about OPTN stock have been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. OptiNose earned a media sentiment score of -1.7 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for OptiNose.

Are investors shorting OptiNose?

OptiNose saw a drop in short interest in the month of January. As of January 31st, there was short interest totalling 7,980,000 shares, a drop of 10.6% from the January 15th total of 8,930,000 shares. Based on an average daily trading volume, of 270,900 shares, the short-interest ratio is presently 29.5 days. Approximately 36.5% of the shares of the company are short sold. View OptiNose's Current Options Chain.

Who are some of OptiNose's key competitors?

What other stocks do shareholders of OptiNose own?

Who are OptiNose's key executives?

OptiNose's management team includes the folowing people:
  • Mr. Peter K. Miller, CEO & Director (Age 58)
  • Dr. Ramy A. Mahmoud M.D., M.P.H., Pres & COO (Age 54)
  • Mr. Keith Alan Goldan, Chief Financial Officer (Age 48)
  • Mr. Michael F. Marino, Chief Legal Officer & Corp. Sec. (Age 43)
  • Mr. Thomas E. Gibbs, Exec. VP & Chief Commercial Officer (Age 47)

When did OptiNose IPO?

(OPTN) raised $101 million in an IPO on Friday, October 13th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO.

Who are OptiNose's major shareholders?

OptiNose's stock is owned by a number of of retail and institutional investors. Top institutional investors include FMR LLC (16.54%), Thrivent Financial for Lutherans (4.09%), Rice Hall James & Associates LLC (3.08%), Franklin Resources Inc. (3.01%), Tamarack Advisers LP (2.53%) and Farallon Capital Management LLC (2.16%). Company insiders that own OptiNose stock include Avista Capital Partners Ii Gp,, Joseph C Scodari, Peter K Miller, Robert P O'neil, Sriram Venkataraman and Thomas Edward Gibbs. View Institutional Ownership Trends for OptiNose.

Which major investors are selling OptiNose stock?

OPTN stock was sold by a variety of institutional investors in the last quarter, including Wildcat Capital Management LLC, Rice Hall James & Associates LLC, Goldman Sachs Group Inc., Credit Suisse AG and UBS Group AG. Company insiders that have sold OptiNose company stock in the last year include Avista Capital Partners Ii Gp, and Thomas Edward Gibbs. View Insider Buying and Selling for OptiNose.

Which major investors are buying OptiNose stock?

OPTN stock was purchased by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, FMR LLC, Franklin Resources Inc., Tamarack Advisers LP, Kornitzer Capital Management Inc. KS, Thrivent Financial for Lutherans, Geode Capital Management LLC and Perceptive Advisors LLC. Company insiders that have bought OptiNose stock in the last two years include Joseph C Scodari, Peter K Miller, Robert P O'neil and Thomas Edward Gibbs. View Insider Buying and Selling for OptiNose.

How do I buy shares of OptiNose?

Shares of OPTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is OptiNose's stock price today?

One share of OPTN stock can currently be purchased for approximately $7.46.

How big of a company is OptiNose?

OptiNose has a market capitalization of $310.19 million and generates $7.07 million in revenue each year. The company earns $-106,660,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis. OptiNose employs 102 workers across the globe.View Additional Information About OptiNose.

What is OptiNose's official website?

The official website for OptiNose is http://www.optinose.com/.

How can I contact OptiNose?

OptiNose's mailing address is 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067. The company can be reached via phone at 267-364-3500 or via email at [email protected]


MarketBeat Community Rating for OptiNose (NASDAQ OPTN)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  208 (Vote Outperform)
Underperform Votes:  229 (Vote Underperform)
Total Votes:  437
MarketBeat's community ratings are surveys of what our community members think about OptiNose and other stocks. Vote "Outperform" if you believe OPTN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPTN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel